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Abstract: In many animal species, as well as in humans, high doses of fentanyl (F) 
produce marked neurotoxic effects, such as muscular rigidity and respiratory depression. 
The antinociception (hot-plate test), impairment of motor coordination (rotarod test) and acute 
toxicity of intraperitoneal newly synthesized analogs, (±)cis-3-carbomethoxy- fentanyl (C) and 
(±)trans-3-carbomethoxyfentanyl (T) were evaluated in mice. The compounds tested 
induced antinociception, impairment of performance on the rotarod, and lethality in a dose-
dependent manner. The relative order of antinociceptive potency was similar to motor 
impairment potency, as well as lethality: F > C > T. Naloxone hydrochloride (1 mg/kg; sc) 
abolished all the effects observed, suggesting that they are mediated via opioid receptors, 
most probably of μ type. There were no significant differences between the therapeutic 
indices of F, C and T. It is concluded, the introduction of 3-carbomethoxy group in the 
piperidine ring of the fentanyl skeleton reduced the potency, but did not affect tolerability 
and safety of the compound. 
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1. Introduction 
Fentanyl (Figure 1) is a strong and relatively short acting opioid drug widely used in surgery and in 
the treatment of postoperative and cancer pain [1]. However, in many animal species, as well as in 
humans, high doses of fentanyl and its analogs produce marked neurotoxic effects such as muscular 
rigidity and respiratory depression [1-4]. Since neurotoxic effects are clinically undesirable, the ability 
to synthesize the compound with less side effects could lead to the development of a new clinically 
valuable opioid drug [2,4-9]. 
Figure 1. Fentanyl, (±)cis-3-carbomethoxyfentanyl and (±)trans-3-carbomethoxyfentanyl. 
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In a previous study it has been found that introduction of 3-carbomethoxy group in the piperidine 
ring of fentanyl skeleton (Figure 1) provides less potent (~2–10 x) opioid analgesics which possess 
rapid onset and a shorter duration of analgesia in rats [4,6-7]. In the present experiments, the 
neurotoxic effect such as impairment of motor coordination and lethality of intraperitoneal fentanyl (F) 
and newly synthesized fentanyl analogs, (±)cis-3-carbomethoxyfentanyl (C) and (±)trans-3-
carbomethoxyfentanyl (T) were compared in mice. 
2. Experimental 
2.1. Animals 
Male albino mice weighting 20–35 g obtained from Military Farm (Belgrade, Serbia) were used. All 
experiments were approved by the Institutional Animal Ethics Committee (Permission N 828/2/2-2, 
May 12th, 2009.) which operates in accordance with Revised Guide for the Care and Use of Laboratory 
Animals (NIH Guide, Volume 25, Number 28, 1996). The animals were housed in groups of 10 in 
plexiglas cages (36.5 × 21 × 14 cm) under standard conditions: temperature of 22 ± 1 °C, and a 12/12 h 
light/dark cycle with lights on at 08.00 h. Food pallets and tap water were available ad libitum, except 
during the experimental procedure. Prior to each experiment the animals were habituated to the 
handling and experimental procedures for at least three consecutive days. Experiments were done in a 
sound–proofed, diffusely illuminated room maintained at a temperature of 22 ± 1 °C. They were 
performed at the same time of the day between 9:00 and 13:00 h to avoid diurnal variation in 
behavioral tests. Experimental groups consisted of 6–10 mice. Each animal was used only once and 
was killed with i.p. injection of sodium thiopental. 
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2.2. Antinociception Testing 
The antinociceptive activity was determined by the “hot plate” test (Technilab Instrument Inc. 475, 
Ugo Basile, Italy). The latency to a “hind paw lick or jump” response was measured for mice placed 
on a plate heated to 55 ± 0.5 °C [10]. In order to minimize tissue damage by repeated testing, a cut-off 
time of 30 s was adopted. This means that the maximum duration of a single exposure of rat to hot 
plate was 30 s. Predrug response latency was obtained 5 min before i.p. drug (or the saline in the 
control group) administration. In control and predrug latency testing, mice that did not respond to hot 
plate within 13 s were excluded from the experiment. 
Postdrug response latency was measured after i.p. administration of test compound (or the saline in 
the control group) at 10, 20, 30, 40, 60, 80 and 100 min. The data are expressed quantally as the 
number of animals in which the antinociception was observed versus total number of animals receiving 
the same treatment. For antinociception, the following criterion was used: an antinociceptive effect 
was said to have occurred if postdrug response latency was doubled in respect to the control latencies. 
The ED50 value for analgesia (AD50) was defined as a dose at which 50% of testing animals doubled 
the control latencies. 
2.3. Impairment of Motor Coordination Testing 
Motor impairment was determined by rotarod test in mice according to Kinnard and Carr [11]. The 
test was undertaken by use of a rod of 3 cm diameter, rotating at a constant speed of 15 rpm (Treadmill 
for mice 7600, Ugo Basile, Milano, Italy). Two days before testing, mice were pretrained and only the 
animals able to remain on the rod for 60 s for two consecutive trials (separated by 30 min pause 
between trials) were used in the experiments. On the day of the experiment, the mice were tested once 
again to obtain the predrug time spent on the rotarod, which had to be at least 60 s for all animals. 
After the i.p. drug administration (or the saline in the control group), the number of animals per group 
unable to remain on the rod for at least 60 s was recorded at 5, 10, 15, 20, 40 and 60 min time points. 
The TD50 (the dose that induces motor impairment in 50% of animals tested) with 95% confidence 
limits was calculated from a corresponding quantal dose–response curve (Litchfield & Wilcoxon I 
procedure) according to Tallarida and Murray [12] by using the following criteria: an animal was said 
to be motorically impaired if it did not remain on the rotarod for the entire 60 s [11]. The ED50 value 
for impairment of motor coordination (TD50) was defined as a dose at which 50% of testing animals 
failed to remain on the rotarod for 60 s. 
2.4. Acute Toxicity 
Acute toxicity was examined with the different intraperitoneal doses of fentanyl, (±)cis-3 
carbomethoxyfentanyl and (±)trans-3-carbomethoxyfentanyl in groups of 10 mice per dose. Lethal end 
points were closely monitored for the first 12 h, and after that, twice per day for 2 weeks. The LD50s 
(median effective doses for lethality) were calculated and compared according to the method of 
Litchfield and Wilcoxon [12]. 
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2.5. Drugs Administration 
Fentanyl citrate (ICN Yugoslavia, Belgrade, Serbia) and (±)cis- and (±)trans-3-carbomethoxy- 
fentanyl oxalate were dissolved in saline and injected i.p. at a final volume of 10 ml/kg. Both (±)cis- 
and (±)trans-3-carbomethoxyfentanyl (Faculty of Chemistry, University of Belgrade, Serbia) were 
examined as a racemic mixture. Doses of the drugs were calculated for the free base. Naloxone 
hydrochloride (Sigma Chemical Co. St. Louis, MO, USA) was also dissolved in saline, and injected sc 
(1 mg/kg) in the back before the i.p. injection of the test compound in the same volume. Saline alone 
(10 mL/kg) was administrated i.p. in a control group of rats. 
2.6. Statistical Analysis 
To permit direct comparison of different compounds and different effects, basic data for each 
animal were transformed to a quantal response (presence or absence of expected drug effect). For each 
effect and each dose maximum response obtained during the time of measurement was used for 
evaluation. Then, computations were done according to the methods of Tallarida and Murray [12]. 
First, the percentages of animals responding were converted to probits and plotted against the log dose. 
Then, the Litchfield & Wilcoxon procedure was used to calculate ED50 (median effective dose) values 
from corresponding quantal dose–response curves. Additionally, when data for a second quantal dose–
response curve was entered, the same procedure calculated the potency ratio [with 95% confidence 
limits (95% CL)] for corresponding curves. In that way, relative potencies for fentanyl, (±)cis-3-
carbomethoxyfentanyl and (±)trans-3-carbomethoxyfentanyl were calculated for antinociceptive, as 
well as toxic effects. Relative potency estimates were considered statistically significantly different 
when 95% CL did not overlap 1.0. Also, the potency ratios between two ED50s (TD50/AD50 and 
LD50/AD50) denoted as the TIs (therapeutic index), for each drug were determined. If the 95% 
confidence interval for a TI fails to include 1.0, then ED50s are significantly different. 
The duration of action was determined as a time that is necessary for antinociception and motor 
impairment to cease in 50% of tested animals after i.p. injection of equi-effective doses (4 × ED50 for 
antinociception) of all three tested compounds. Percentages of responding rats for each effect and each 
compound was plotted as a function of time. 
The drug response was compared to the control response at each time point of measurement by 
using Fisher’s test. The difference in time-effect course between equi-antinociceptive doses of all three 
compounds tested was estimated by using both Fisher’s and Mann-Whitney test. A P value of less than 
0.05 was considered statistically significant. 
3. Results and Discussion 
The present study showed that fentanyl and its newly synthesized analogs, (±)cis-3-carbomethoxy- 
fentanyl (C) and (±)trans-3-carbomethoxyfentanyl (T), caused a significant and dose-dependent 
antinociception, impairment of motor coordination and lethality in mice. For each effect tested, probit 
slopes for F, C and T are not significantly different (p > 0.05, test for parallelism) (Table 1; Figure 2). 
The relative potencies for F, C and T are presented in Table 1. 
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Figure 2. Log dose-probit curves for antinociception (hot plate) (A), motor impairment 
(rotarod test) (B) and lethality (C) for fentanyl, (±)cis-3-carbomethoxyfentanyl and (±)trans- 
3-carbomethoxyfentanyl, in mice, after i.p. drug administration. For antinociception, the 
following criterion was used: an antinociceptive effect was said to have occurred if postdrug 
response latency was doubled in respect to the control predrug latencies. Motor impairment 
was detected in the animal unable to maintain equilibrium on the rotating rod for 60 s. Each 
point represents the probit value obtained from at least 6 mice. 
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Table 1. Median effective doses for antinociception (AD50), impairement of motor 
coordination (TD50) and lethality (LD50), correlation coefficient (r), probit slopes and 
relative potencies with 95% confidence limits (95% CL) for fentanyl, (±)cis-3-
carbomethoxyfentanyl and (±)trans-3-carbomethoxyfentanyl in inducing antinociception, 
impairement of motor coordination and lethality in mice. 
Effect 
AD50 or TD50 or LD50 
(95% confidence 
interval) 
r Probit slope Relative potency 
Fentanyl (0.017–63.096 mg/kg) 
Antinociception 1 0.025 (0.018–0.034) 0.979 3.9 (−6.4–14.3) 1 
Impairement of 
motor coordination 2 
0.073 (0.043–0.123) 0.999 2.9 (1.3–4.5) 1 
Lethality     
24 h 26.30 (14.78–46.77) 0.990 2.0 (1.1–2.9) 1 
14 days 21.25 (11.99–37.67) 0.994 2.5 (1.6–3.3) 1 
(±)cis-3-Carbomethoxyfentanyl (0.032–128.825 mg/kg) 
Antinociception 1 0.071 (0.040-0.124) 1 2.3 (1.7–2.8) 0.35* (0.18–0.67) 
Impairement of 
motor coordination 2 
0.282 (0.188-0.421) 0.993 3.5 (−1.8–8.9) 0.26* (0.13–0.50) 
Lethality     
24 h 82.71 (43.73–156.46) 0.981 1.8 (0.7–2.9) 0.32 * (0.13–0.75) 
14 days 65.12 (34.51–122.85) 0.999 1.8 (1.6–2.0) 0.33 * (0.14–0.77) 
(±)trans-3-Carbomethoxyfentanyl (0.145–3.097 mg/kg) 
Antinociception 1 0.32 (0.21–0.50) 0.994 2.9 (−1.2–7.1) 0.08* (0.01–0.58) 
Impairement of 
motor coordination 2 
1.63 (1.20–2.20) 0.949 4.9 (−15.6–25.3) 0.04* (0.01–0.24) 
1 criterion > double control latency; 2 criterion < 60 s, AD50s, TD50s and LD50 were calculated by 
using at least 3 doses of testing compound. One dose is tested in 6-10 mice (Litchfield &Wilcoxon 
test) [12]; * Relative potency estimates were considered statistically significant when 95% CL did 
not overlap 1.0 (P < 0.05, Litchfield & Wilcoxon II test) [12]. 
This is the first report on the toxicity of C and T. C- and T-induced antinociception in the hot plate test 
in mice is consistent with the ability of these drugs to reduce tail immersion latency in rats [4]. In 
comparison with F (0.017–0.037 mg/kg), the antinociceptive potencies of C (0.032–0.125 mg/kg), and 
T (0.145–0.631 mg/kg), were reduced by factor 3 and 14, respectively (P < 0.05) (Figure 2; Table 1). 
Also, in comparison with F (0.046–0.186 mg/kg), the potencies of C (0.155–0.619 mg/kg), and T 
(1.291–3.097 mg/kg) to induce the motor impairment, were reduced about 4 and 25 times, respectively 
(P < 0.05) (Figure 2; Table 1). Also, C (16.26–128.83 mg/kg) is about 3 times less potent in producing 
lethal effect than fentanyl (6.31–63.10 mg/kg) (P < 0.05) (Figure 2; Table 1). T is a significantly less 
potent drug than C (4.6 and 5.8 times for analgesia and motor impairment, respectively) (not shown). 
Each of the tested compounds, exhibited similar (p > 0.05) relative potencies in producing all effects tested 
(95% confidence intervals overlap) (Table 1). If a series of related agonists exhibits identical relative 
potencies in producing distinct effects, it is likely that these effects are mediated by similar or identical 
receptor molecules [13]. 
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Both, antinociceptive and toxic effects, were abolished by pretreatment with naloxone hydrochloride 
(1 mg/kg), nonselective antagonist of opioid receptors (not shown), indicating that they are mediated by 
opioid receptors. In the case of F, C and T, they are of μ type, most probably. Most of the currently 
available strong opioids exert their analgesic and adverse effects primarily through the opioid μ 
receptors [14]. 
The therapeutic indices are shown in Table 2. As F, C, and T did not alter rotarod performance in the 
antinociceptive doses used, it is possible that the antinociceptive behavior was not due to motor impairment 
or sedation. All drugs tested demonstrated good separation between antinociceptive efficacy in a thermal 
pain model, and motor impairment induction. The TD50 values for F, C, and T are significantly greater than 
their AD50 values [2.9 (1.6–5.4), 4.0 (2.0–7.9) and 5.0 (3.0–8.5) times, respectively] (Table 2). The 
greater the TI value is, the greater is observed drug tolerability. There are no significant differences 
between therapeutic indices for F, C and T, which means that these compounds are equally tolerable in 
regard to motor impairment. These observations suggest that C and T are effective drugs in hot plate test in 
mice, in a dose range that is not related to motor impairment, and that in comparison with fentanyl C and T 
are less potent, but not less tolerable drugs. 
Table 2. Therapeutic indices for fentanyl, (±)cis 3-carbomethoxy fentanyl and (±)trans 3-
carbomethoxy fentanyl in mice. 
Compound Fentanyl 
(±)cis- 
3-carbomethoxy- 
fentanyl 
(±)trans- 
3-carbomethoxy- 
fentanyl 
Toxicity  Therapeutic index 
(TI = TD50/AD50 or 
LD50/AD50) 
Therapeutic index 
(TI = TD50/AD50 or 
LD50/AD50) 
Therapeutic index  
(TI = TD50/AD50 or 
LD50/AD50) 
Impairment of motor 
coordination (rotarod) 2 
2.9 
(1.6–5.4) 
4.0 
(2.0–7.9) 
5.0  
(3.0–8.5) 
Lethality 
(24 h) 
(14 days) 
 
1061.8 
(548.9–2053.8) 
858.1  
(444.9–1654.7) 
1166.7 
(497.9–2733.2) 
918.5 
(392.8–2147.5) 
/ 
 
1 criterion > double control latency; 2 criterion < 60 s; AD50 = median effective dose for 
antinociception; TD50 = median effective dose for impairment of motor coordination (median toxic 
dose); LD50 = median lethal dose; Potency ratios TD50/AD50 and LD50/AD50 denoted as the TIs 
(therapeutic indices), for each drug were determined. If the 95% confidence interval for a TI fails to 
include 1.0, then ED50s are significantly different. 
By using equi-antinociceptive doses (4 × ED50), C and T produced shorter duration of action than F. 
The duration of actions (time that is necessary for drug response to cease in 50% of tested animals) were 
approximately 80, 40 and 40 min (antinociception) and 10, 5 and 5 min (impairment of motor 
coordination) for F, C and T, respectively. The duration of antinociception of C and T was not statistically 
different from F (p > 0.05; Mann-Whitney test), but the duration of motor impairment of T was 
statistically reduced (P < 0.01) in comparison with F (Figure 3 and 4). This is not the case with C. In our 
previous experiments it has been clearly shown that C and T given i.p. in rats exhibited significantly 
shorter antinociception in comparison with F [4]. On that occasion, the differences in duration of action 
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were explained by a different pharmacokinetics between fentanyl and 3-carbomethoxy fentanyl. Moreover, 
the present finding suggests species differences in the pharmacokinetics of 3-carbomethoxyfentanyl. 
Figure 3. Time course of the antinociceptive effects of A) fentanyl, B) (±)cis-3-
carbomethoxyfentanyl and C) (±)trans-3-carbomethoxyfentanyl in mice. The incidence of 
antinociception is plotted as a function of time after i.p. injection of equi-effective doses 
i.e. 4 × ED50 for antinociception of each drug. Each drug was tested by using 6-10 rats. 
Each point represents the percentage of rats that respond to the treatment with doubled 
postdrug response latency. Control animals (n = 7) received saline in the same volume. 
# P < 0.05 and ## P <0.01 indicate a significant difference of the responses of fentanyl 
analogs in comparison to control (Fisher’s test). 
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Figure 4. Time course of the effects of A) fentanyl, B) (±)cis-3-carbomethoxyfentanyl and 
C) (±)trans-3-carbomethoxyfentanyl on motor performance of mice. The incidence of 
motor impairment is plotted as a function of time after i.p. injection of equi-effective doses 
i.e. 4xED50 for antinociception of each drug. Each drug was tested by using 6–10 rats. 
Each point represents the percentage of rats that respond according to criterion: >20, 
20–39, 40–59 and >60 s spent on rotarod. * P < 0.05 and ** P < 0.01 (Mann-Whitney test) 
indicate a significant difference of the responses of (±)cis- or trans-3-carbomethoxy- 
fentanyl in comparison to fentanyl. # P < 0.05 and ## P < 0.01 indicate a significant 
difference of the responses of fentanyl analogs in comparison to control (Fisher’s test). 
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Acute toxicities of F and C have been evaluated in mice. The animals have been followed up for 
14 days. There is no difference between LD50 values obtained after 24 h and 14 days. Signs and symptoms 
of acute toxicity of all three drugs were similar: dyspnea, hypoventilation, cyanosis, convulsion, Straub tail, 
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trunk muscle rigidity, prostration etc. In agreement with opioid activity, respiratory depression was the 
most prominent symptom and probably the main cause of death, as well [15]. This is supported by fact that 
most death occurred in the first few hours after drug administration. Necropsy has not been performed. 
There is no significant difference between the therapeutic indices [median lethal dose (LD50) / median 
antinociceptive dose (AD50)] between F and C: 858.1 (444.9–1654.7) and 918.5 (392.8–2147.5), 
respectively (Table 2). This finding suggested that F and C are equally safe in mice. 
4. Conclusion 
In conclusion, the antinociceptive and toxic effects of newly synthesized fentanyl analogs, (±)cis-3-
carbomethoxyfentanyl and (±)trans-3-carbomethoxyfentanyl are mediated via opioid receptors, most 
probably of μ type. The introduction of 3-carbomethoxy group in the piperidine ring of the fentanyl 
skeleton reduced the potency, but did not affect tolerability and safety of the compound. 
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